| scholarly article | Q13442814 |
| P50 | author | Gregory Germino | Q55965628 |
| P2093 | author name string | Luis Fernando Menezes | |
| P2860 | cites work | The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein | Q24292750 |
| NEK8 mutations affect ciliary and centrosomal localization and may cause nephronophthisis | Q24306642 | ||
| Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis | Q24310102 | ||
| NEK1 mutations cause short-rib polydactyly syndrome type majewski | Q24324062 | ||
| Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease | Q24531988 | ||
| The mammalian gene function resource: the International Knockout Mouse Consortium | Q24631451 | ||
| Mutations in a NIMA-related kinase gene, Nek1, cause pleiotropic effects including a progressive polycystic kidney disease in mice | Q24648390 | ||
| Pkd1 and Pkd2 are required for normal placental development | Q27319907 | ||
| Mutations in SEC63 cause autosomal dominant polycystic liver disease | Q28260838 | ||
| Design, power, and interpretation of studies in the standard murine model of ALS | Q28268686 | ||
| Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene | Q28507278 | ||
| The ion channel polycystin-2 is required for left-right axis determination in mice | Q28508558 | ||
| Cardiac defects and renal failure in mice with targeted mutations in Pkd2 | Q28510555 | ||
| Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease | Q28586859 | ||
| A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation | Q28590393 | ||
| Fibrocystin/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function | Q28594258 | ||
| Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease | Q29037884 | ||
| Systematic review of the empirical evidence of study publication bias and outcome reporting bias | Q29619094 | ||
| Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. | Q33702386 | ||
| Molecular advances in autosomal dominant polycystic kidney disease | Q33723862 | ||
| Evidence of extraordinary growth in the progressive enlargement of renal cysts | Q33827400 | ||
| Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease | Q33979298 | ||
| Network analysis of a Pkd1-mouse model of autosomal dominant polycystic kidney disease identifies HNF4α as a disease modifier. | Q34499444 | ||
| The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease | Q34600282 | ||
| The APL paradigm and the "co-clinical trial" project | Q35568084 | ||
| Epitope-tagged Pkhd1 tracks the processing, secretion, and localization of fibrocystin. | Q35647871 | ||
| PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats | Q35764727 | ||
| Genetic interaction studies link autosomal dominant and recessive polycystic kidney disease in a common pathway. | Q36158232 | ||
| Mutations of HNF-1beta inhibit epithelial morphogenesis through dysregulation of SOCS-3. | Q36299972 | ||
| Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity | Q36357916 | ||
| A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1 | Q36549183 | ||
| Biliary and pancreatic dysgenesis in mice harboring a mutation in Pkhd1. | Q36559697 | ||
| Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. | Q36739229 | ||
| Cilia at the node of mouse embryos sense fluid flow for left-right determination via Pkd2 | Q37011684 | ||
| Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. | Q37092766 | ||
| Renal injury is a third hit promoting rapid development of adult polycystic kidney disease | Q37239858 | ||
| Polycystic kidney disease, cilia, and planar polarity. | Q37723498 | ||
| A transcriptional network in polycystic kidney disease | Q40775992 | ||
| Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways | Q42452939 | ||
| Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease | Q42927109 | ||
| mTOR inhibitors in polycystic kidney disease. | Q43004248 | ||
| Everolimus in patients with autosomal dominant polycystic kidney disease. | Q43004249 | ||
| Sirolimus and kidney growth in autosomal dominant polycystic kidney disease | Q43004251 | ||
| Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). | Q43069328 | ||
| Autosomal Recessive Polycystic Kidney Disease: The Clinical Experience in North America | Q44503166 | ||
| Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease | Q45162599 | ||
| Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. | Q45281061 | ||
| Gene editing: not just for translation anymore | Q46216698 | ||
| Model organisms: There's more to life than rats and flies | Q46377715 | ||
| Missense mutation in sterile alpha motif of novel protein SamCystin is associated with polycystic kidney disease in (cy/+) rat. | Q46738223 | ||
| Kidney cysts, pancreatic cysts, and biliary disease in a mouse model of autosomal recessive polycystic kidney disease | Q46744622 | ||
| Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). | Q46749984 | ||
| A defect in a novel Nek-family kinase causes cystic kidney disease in the mouse and in zebrafish | Q47073857 | ||
| Identification and characterization of Pkhd1, the mouse orthologue of the human ARPKD gene | Q48286475 | ||
| A mouse model of autosomal recessive polycystic kidney disease with biliary duct and proximal tubule dilatation. | Q51752480 | ||
| Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. | Q53563592 | ||
| Kinesin Family Member 12 Is a Candidate Polycystic Kidney Disease Modifier in the cpk Mouse | Q57314438 | ||
| A mouse model for cystic biliary dysgenesis in autosomal recessive polycystic kidney disease (ARPKD) | Q57908850 | ||
| Somatic inactivation of Pkd2 results in polycystic kidney disease | Q74502174 | ||
| Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease | Q76390332 | ||
| Comparison of Pkd1-targeted mutants reveals that loss of polycystin-1 causes cystogenesis and bone defects | Q77105186 | ||
| Late onset of renal and hepatic cysts in Pkd1-targeted heterozygotes | Q78167116 | ||
| Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist | Q79075547 | ||
| A functional floxed allele of Pkd1 that can be conditionally inactivated in vivo | Q81096232 | ||
| P433 | issue | 3-4 | |
| P921 | main subject | murine model | Q122890741 |
| P304 | page(s) | e153-e158 | |
| P577 | publication date | 2013-12-01 | |
| P1433 | published in | Drug discovery today. Disease mechanisms | Q27721894 |
| P1476 | title | Murine Models of Polycystic Kidney Disease | |
| P478 | volume | 10 |
| Q37049561 | Differences in the timing and magnitude of Pkd1 gene deletion determine the severity of polycystic kidney disease in an orthologous mouse model of ADPKD. | cites work | P2860 |
Search more.